Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2018006804) ORPHAN NUCLEAR RECEPTOR NUR77 LIGAND AND APPLICATION THEREOF
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2018/006804 International Application No.: PCT/CN2017/091726
Publication Date: 11.01.2018 International Filing Date: 04.07.2017
IPC:
C07J 63/00 (2006.01) ,A61K 31/56 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
J
STEROIDS
63
Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
56
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
厦门大学 XIAMEN UNIVERSITY [CN/CN]; 中国福建省厦门市 思明区思明南路422号 No. 422 Si Ming Nan Road, Siming District Xiamen, Fujian 361005, CN
Inventors:
张晓坤 ZHANG, Xiaokun; CN
林祥志 LIN, Xiangzhi; CN
苏迎 SU, Ying; CN
曾志平 ZENG, Zhiping; CN
胡梦婕 HU, Mengjie; CN
罗强 LUO, Qiang; CN
朱怡 ZHU, Yi; CN
古丽米然⋅阿里同别克 GULIMIRAN, Alitongbieke; CN
Agent:
中国国际贸易促进委员会专利商标事务所 CCPIT PATENT AND TRADEMARK LAW OFFICE; 中国北京市 西城区阜成门外大街2号万通新世界广场8层 8th Floor, Vantone New World Plaza, 2 Fuchengmenwai Street, Xicheng District Beijing 100037, CN
Priority Data:
201610520308.804.07.2016CN
Title (EN) ORPHAN NUCLEAR RECEPTOR NUR77 LIGAND AND APPLICATION THEREOF
(FR) LIGAND DE RÉCEPTEUR NUCLÉAIRE ORPHELIN NUR77 ET SON APPLICATION
(ZH) 孤儿核受体Nur77的配体及其用途
Abstract:
(EN) Provided are an application of a compound represented by formula I as a ligand of an orphan nuclear receptor Nur77, and an application for preventing or treating a disease related to the orphan nuclear receptor Nur77.
(FR) L'invention concerne une application d'un composé représenté par la formule I en tant qu'un ligand du récepteur nucléaire orphelin Nur77, et une application pour prévenir ou traiter une maladie liée au récepteur nucléaire orphelin Nur77.
(ZH) 提供如式I所示的化合物用作孤儿核受体Nur77的配体的用途、用于预防或治疗与孤儿核受体Nur77相关的疾病的用途。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)
Also published as:
CN108026141EP3480207